10-Q Summary: Reneo Pharmaceuticals, Inc.
Filing identity: The supplied filing is for Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), not OnKure Therapeutics, Inc. Investors should verify that this is the intended filing. The report covers the unaudited quarter ended March 31, 2023 and was filed May 11, 2023.
Business context and reporting period
Reneo is a clinical-stage pharmaceutical company developing mavodelpar (REN001), an oral PPARδ agonist for rare genetic mitochondrial diseases, including primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). The company has no approved products and has not generated product revenue.
- The pivotal Phase 2b STRIDE study in PMM completed enrollment of 213 patients in March 2023, above the 200-patient target.
- Management expects topline STRIDE results in the fourth quarter of 2023 and potentially plans to file an NDA in the first half of 2024.
- The STRIDE AHEAD open-label extension had enrolled more than 100 patients, with more than 50 reaching six months; enrollment of patients with nuclear DNA-related PMM was expected to begin in the second quarter of 2023.
Financial performance and liquidity
| Metric | Three months ended March 31, 2023 | Three months ended March 31, 2022 |
|---|---|---|
| Research and development expense | $11.0 million | $9.3 million |
| General and administrative expense | $5.1 million | $3.7 million |
| Total operating expenses | $16.1 million | $13.0 million |
| Other income (loss) | $1.0 million | $(0.02) million |
| Net loss | $15.1 million | $13.0 million |
| Net loss per share | $0.60 | $0.53 |
| Net cash used in operating activities | $9.0 million | $9.0 million |
- Cash and cash equivalents were $30.4 million at March 31, 2023, compared with $19.9 million at December 31, 2022.
- Short-term investments were $63.4 million, producing total cash, cash equivalents and short-term investments of approximately $93.8 million.
- Total assets were $98.9 million and stockholders’ equity was $87.1 million at March 31, 2023.
- Accumulated deficit was $151.8 million.
- The filing reports no material debt; liabilities primarily consisted of accounts payable, accrued expenses, operating lease liabilities and a $0.3 million CEO performance award liability.
- Net cash provided by investing activities was $18.5 million, primarily reflecting maturities of short-term investments. Net cash provided by financing activities was $1.0 million from the at-the-market facility.
- Operating expenses increased $3.1 million year over year. R&D growth was primarily attributable to clinical study costs, while G&A growth reflected higher facility and personnel costs.
Material changes versus the prior comparable period
- R&D expense increased $1.7 million, or approximately 18%, mainly because of higher clinical and regulatory costs supporting mavodelpar registration activities.
- G&A expense increased $1.4 million, or approximately 37%, primarily because of additional headcount and related facility and personnel costs.
- Net loss increased $2.1 million, or approximately 16%, despite a $1.0 million improvement in other income due to higher interest rates on investments.
- Shares outstanding increased to 25.1 million from 24.7 million at December 31, 2022, including approximately 407,877 shares issued under the ATM facility during the quarter.
- Stock-based compensation expense was $1.2 million, compared with $1.1 million in the prior-year quarter.
Guidance, outlook, risks and unusual items
- Management expects R&D and G&A expenses to increase as clinical development and regulatory activities advance.
- Management concluded that substantial doubt exists about the company’s ability to continue as a going concern because existing resources, including subsequent financing proceeds, are not expected to fund operations for more than one year after the filing date.
- On May 8, 2023, the company completed a public offering of 7,906,250 shares at $8.00 per share, generating approximately $58.2 million of net proceeds. On May 9, 2023, it completed a private placement of 625,000 shares at $8.00 per share, generating approximately $4.7 million of net proceeds.
- In April 2023, the company entered into a non-binding term sheet for up to $100 million of conditional, tranched structured royalty financing. The proposed financing was not definitive and was subject to further diligence and documentation.
- The company depends entirely on the development and regulatory approval of mavodelpar. Key risks include clinical trial failure or delay, patient-enrollment constraints in rare diseases, safety findings, regulatory uncertainty, reliance on contract research organizations and manufacturers, intellectual-property challenges, and the need for substantial additional capital.
- The vTv license agreement provides rights to mavodelpar but requires potential development and regulatory milestone payments of up to $64.5 million, sales-based milestones of up to $30.0 million, and tiered royalties on future net sales. No milestone payments were recorded in the quarter.
- The company maintains operating accounts with SVB US and SVB UK and disclosed risks related to disruption or liquidity problems affecting financial institutions.
- Disclosure controls and procedures were determined to be effective as of March 31, 2023. The company implemented an integrated accounting and consolidation system during the quarter.
Facts investors should verify
- Confirm the issuer: the supplied filing identifies Reneo Pharmaceuticals, Inc., whereas the request identifies OnKure Therapeutics, Inc.
- Verify the completion, net proceeds and dilution effects of the May 2023 public offering and private placement.
- Monitor STRIDE topline results expected in the fourth quarter of 2023 and the potential NDA filing target for the first half of 2024.
- Assess the going-concern disclosure, projected cash runway and the company’s ability to secure additional financing.
- Review the terms and closing status of the proposed structured royalty financing, which was non-binding as of the filing.
- Evaluate clinical efficacy, safety, manufacturing and regulatory risks for mavodelpar, as well as the scope and remaining term of licensed intellectual-property protection.